Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,073.23 -3.75 (-0.35%)

Streaming Delayed Price Updated: 2:49 PM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? ↗

November 10, 2025

Via Stocktwits

Markets Cheer As Shutdown End Nears: These 15 Stocks Are Rallying ↗

November 10, 2025

Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown in history.

Via Benzinga

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration ↗

November 10, 2025

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4.

Via Benzinga

This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 10, 2025

Via Benzinga

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 10, 2025

Via Benzinga

12 Analysts Have This To Say About Eli Lilly ↗

November 10, 2025

Via Benzinga

This Eli Lilly Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

November 10, 2025

Via Benzinga

2 Monster Stocks in the Making ↗

November 10, 2025

There might still be time to get in on the ground floor.

Via The Motley Fool

2 Growth Stocks with All-Star Potential and 1 We Question

November 09, 2025

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...

Via StockStory

3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs ↗

November 09, 2025

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Via The Motley Fool

The Algorithmic Imperative: Navigating AI’s Ethical Labyrinth in American Healthcare

November 09, 2025

As of November 2025, Artificial Intelligence (AI) has rapidly transitioned from a futuristic concept to an indispensable tool in American healthcare, profoundly reshaping diagnostics, treatment, and...

Via TokenRing AI

Topics Artificial Intelligence

Is There a Future for Viking Therapeutics? ↗

November 09, 2025

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

Via The Motley Fool

Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump ↗

November 09, 2025

The companies announced a huge deal that will have implications for investors.

Via The Motley Fool

Topics World Trade

Organon (OGN) Reports Earnings Tomorrow: What To Expect

November 08, 2025

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points ↗

November 08, 2025

Eli Lilly stock and a pair of AI plays lead this watch list of stocks near buy points as the S&P 500 makes a stand at a key support level.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy ↗

November 08, 2025

The stock didn't stay down for too long.

Via The Motley Fool

Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030 ↗

November 08, 2025

It could become the first trillion-dollar pharmaceutical company in the process.

Via The Motley Fool

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. ↗

November 08, 2025

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.

Via The Motley Fool

Topics Government

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗

November 08, 2025

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."

Via Benzinga

Why Novo Nordisk Stock Is Sinking This Week ↗

November 07, 2025

The global drugmaker is facing some headwinds related to tough competition.

Via The Motley Fool

Topics Government World Trade

S&P 500: The Bull Market Is Just Getting Started

November 07, 2025

The S&P 500 has been on an impressive ascent, with market sentiment in November 2025 largely skewed towards cautious optimism. After a robust year of gains, driven significantly by the "mania around...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Why Nvidia (NVDA) Stock Is Falling Today

November 07, 2025

Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and...

Via StockStory

Topics Artificial Intelligence

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment ↗

November 07, 2025

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

Via Benzinga

Navigating the Shifting Tides: Experts Chart Course for 2025 Stock Market

November 07, 2025

As the calendar turns towards late 2025, leading financial experts are providing a detailed compass for investors, navigating a stock market characterized by cautious optimism, elevated valuations, and...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report ↗

November 07, 2025

The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack.

Via Stocktwits

Topics Government

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data ↗

November 06, 2025

Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target.

Via Stocktwits

Topics Government World Trade

Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗

November 06, 2025

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.

Via Stocktwits

Topics Government World Trade

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗

November 06, 2025

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

Via Benzinga

Topics Government

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.